Every year, about 10 million people die of cancer worldwide; in Taiwan, cancer has been in the top ten causes of death for more than 40 years. Cancer is a serious issue that people are reluctant to talk about and address.
Aside from the disease itself, for most patients, what truly causes suffering is the side effects of treatment and the risks of the "trial-and-error" approach to medication use.
“Put The Patient First” is our company's highest priority. Our goal is to reduce the pain and risks experienced by cancer patients during treatment and to enhance the precision of medication use during the golden window of treatment.
Current cancer treatments primarily rely on standard treatment protocols and doctors' experience-based predictions. However, individual differences mean that treatment methods affect each patient differently. Through our services, doctors can understand the actual effectiveness of drugs on a patient's cancer cells, allowing them to further tailor treatment plans to the patient's condition and reduce the risks of patients testing medications on themselves while fighting cancer.
We aspire to be the guardian of cancer patients and the partner of healthcare professionals. Together， We can make this world CancerFree !
Based on innovative precision medicine, CancerFree Biotech adheres to three core management philosophies:
"Put The Patient First"
"Uphold Scientific Expertise"
"Deepen Precision Medicine"
We continuously research and improve biomedical technologies, bringing laboratory research results to human life and promoting medical advancement.
CancerFree Biotech is a vibrant and energetic startup team, which is different from traditional Taiwanese biotech companies. We firmly believe in strategic human resource management, viewing employee growth as our most important asset and developing a people-oriented corporate culture. We assist our colleagues in developing professional competencies through cross-domain projects.
© 2025 All Right Reserved
曾在美國紐約摩根史坦利（Morgan Stanley）工作十餘年，專注於金融領域的 Data Security。然而，2015 年父親罹患癌症，在陪伴治療的過程中，發現癌症藥物治療的精準度仍有許多改進空間，深刻體會到病患在治療過程中承受的風險與痛苦。當接觸到臺北醫學大學的一項創新技術時，認識到其臨床應用潛力，可能幫助醫師病人降低用藥風險，因此毅然決然地決定回台發展這項技術。2018年底，成立精拓生技，以 E.V.A. (Ex Vivo Avatar) 腫瘤體外替身技術為核心，致力於提供更精準的癌症治療方案。這項技術的發展，不僅是對個人信念的實踐，更是一場與時間競賽的挑戰，期望為癌症患者帶來更多治療選擇與希望。
創業的過程充滿挑戰，但使命感成為前進的動力。Po曾在觀賞《神力女超人》（Wonder Woman）時，聽到一句臺詞：「If you see something wrong happening in the world, you can either do nothing, or you can do something.」（如果你目睹世間的不義與錯誤，你可以選擇視而不見，亦可選擇挺身而出）。這句話進一步強化了自己的決心，讓創業不再只是想法，而是付諸行動的承諾。
從小因家人罹癌，因此想要更了解癌症幫助患者走過病程，於國立陽明交通大學臨床醫學所開始研究頭頸癌的代謝及轉移機制，對於癌症治療的挑戰充滿熱情。求學期間深刻認識到研究與實際應用間的巨大落差，期待將最新的研究帶入臨床，將複雜的醫學概念轉化為可行的創新療法。
Amber於 2018 年踏入創業領域，共同創立精拓生技，致力於透過突破性的技術解決現有癌症治療問題，並負責公司內外部事務，促進公司內部跨部門合作，推動技術創新，促進臨床溝通與發展。
在 9 個國家、1,000 多個團隊中參與 Meet the Drapers 矽谷新創募資實境秀，奪得世界冠軍並獲得 100 萬美元投資獎金，充分展現臺灣創業家的韌性及國際競爭力。從國科會「創新創業激勵計畫 (From IP to IPO, FITI)」嶄露頭角，後續參與許多女性創業加速器，如飛雁計畫、AWE女性創業學院及渣打女力創業計畫，在新創領域追求成長。
現任臺北醫學大學附設醫院放射腫瘤科主治醫師，並兼任臺北醫學大學醫學工程學院生醫材料暨組織工程研究所副教授、癌症轉譯研究中心副主任，專精於癌症放射治療、立體定位放射治療及癌症精準醫學諮詢。長期投入精準醫學的發展與應用，並積極參與細胞治療與再生醫學研究，持續推動癌症治療技術的創新與進步。
擁有國立台灣大學醫學系學士學位及國立台灣大學藥理學研究所博士學位，並曾於美國休士頓安德森癌症中心與德州心臟研究所擔任博士後研究員。在臨床工作中，他深刻體會到癌症治療仍存在的不足之處，因此積極組建跨領域專家團隊，結合臨床需求與創新技術，研發出突破性的解決方案。這項技術不僅提升癌症治療的精準度，也獲得國家新創獎的肯定，展現其在醫療創新領域的影響力。
va Hung brings extensive experience in human resources, having held key HR positions at leading international technology companies, including Google and Microsoft. Her expertise encompasses organizational development, corporate culture building, coaching leadership, and talent acquisition. Notably, she contributed to the establishment of overseas branches of Google Inc. and played a pivotal role during the formative years of Google Taiwan, gaining substantial cross-cultural and high-growth enterprise experience.
Eva holds an MBA from Pennsylvania State University in the United States. Additionally, she has a background in Montessori early childhood education and has served as a teacher at Waterfront Montessori School, demonstrating her deep passion for education and human-centered care.
As a mother of three, Eva has developed unique insights into communication and personal growth, which she integrates into corporate culture and HR strategies. She firmly believes that sustainable development and mutual prosperity with talent are core drivers propelling a company forward. Currently, as the Chief Human Resources Officer at CancerFree Biotech, she is dedicated to fostering a mission-driven and highly collaborative organizational environment, promoting collective growth for both the company and its teams.
We aspire to be a guardian of cancer patients and a partner to medical professionals.
Po Chen worked for over a decade at Morgan Stanley in New York, focusing on data security within the financial sector. However, in 2015, when his father was diagnosed with cancer, Po became deeply involved in his father’s treatment and recognized the significant gaps in the precision of cancer drug therapies. He realized the immense risks and suffering cancer patients face during treatment. Upon encountering an innovative technology from Taipei Medical University, Po recognized its clinical potential to reduce medication risks for both doctors and patients. Motivated by this discovery, he made the bold decision to return to Taiwan and develop this technology.
In late 2018, Po founded CancerFree Biotech, with its core technology being the E.V.A. (Ex Vivo Avatar) tumor model. The company is dedicated to providing more precise cancer treatment solutions. The development of this technology is not just a personal belief but also a race against time to offer more treatment options and hope to cancer patients.
Entrepreneurship has been challenging, but Po’s sense of mission has been the driving force. He recalls a line from the movie Wonder Woman that resonated with him: “If you see something wrong happening in the world, you can either do nothing, or you can do something.” This quote strengthened his resolve, turning his entrepreneurial idea into a commitment to action.
Amber Wu, inspired by her family’s experience with cancer, became passionate about understanding cancer and helping patients through their treatment journey. She began researching the metabolism and metastasis mechanisms of head and neck cancer at National Yang Ming Chiao Tung University. Amber realized during her studies that there was a significant gap between research and clinical application. This insight motivated her to bridge the gap by bringing the latest research into clinical practice and turning complex medical concepts into actionable, innovative therapies.
In 2018, Amber co-founded CancerFree Biotech, where she is committed to solving existing cancer treatment challenges through groundbreaking technologies. She manages both internal and external affairs, promotes cross-department collaboration, drives technical innovations, and fosters communication between clinical and development teams.
Amber’s entrepreneurial journey reached a milestone when she won Meet the Drapers, a Silicon Valley reality show featuring over 1,000 teams from 9 countries. As the world champion, Amber received a $1 million investment from Tim Draper. Her resilience and international competitiveness have been showcased through her involvement in several female entrepreneur accelerators, such as Flyer Program, AWE Women’s Entrepreneurship Academy, and Standard Chartered Women Entrepreneurs Program.
Long-sheng Lu is an attending physician at the Department of Radiation Oncology, Taipei Medical University Hospital, and an associate professor at the Institute of Biomedical Materials and Engineering and the Cancer Translational Research Center at Taipei Medical University. Specializing in radiation therapy, stereotactic radiation therapy, and precision cancer medicine consultation, Dr. Lu has dedicated much of his career to the development and application of precision medicine. He is also actively involved in cellular therapy and regenerative medicine research, continually pushing for innovation in cancer treatment technologies.
Dr. Lu holds a Bachelor’s degree in Medicine from National Taiwan University and a Ph.D. in Pharmacology from National Taiwan University. He completed postdoctoral research at the MD Anderson Cancer Center and the Texas Heart Institute in the United States.
In clinical practice, Dr. Lu has recognized the remaining challenges in cancer treatment and has actively built a multidisciplinary expert team to combine clinical needs with innovative technologies. This collaboration led to the development of groundbreaking solutions that not only improve cancer treatment precision but also received recognition with the National Innovation Award, showcasing his impact in the field of medical innovation.
